These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23997350)

  • 1. Cytomegalovirus disease in renal transplant recipients: a single-center experience.
    Bhadauria D; Sharma RK; Kaul A; Prasad N; Gupta A; Gupta A; Srivastava A
    Indian J Microbiol; 2012 Sep; 52(3):510-5. PubMed ID: 23997350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus disease in renal transplant recipients: a single-center experience.
    Cavdar C; Celtik A; Saglam F; Sifil A; Atila K; Celik A; Tosun P; Olmuscelik O; Bora S; Gulay H; Camsari T
    Ren Fail; 2008; 30(5):503-6. PubMed ID: 18569930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?
    Basic-Jukic N; Kes P; Bubic-Filipi LJ; Puretic Z; Brunetta B; Pasini J
    Transplant Proc; 2005 Mar; 37(2):850-1. PubMed ID: 15848553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
    Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK; Pouch SM; Kissling KT
    Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.
    Triemer HL; Pearson TC; Odom KL; Larsen CP
    Clin Transplant; 2000 Aug; 14(4 Pt 2):413-20. PubMed ID: 10946781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM; Keating GM
    Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction.
    Giral M; Nguyen JM; Daguin P; Hourmant M; Cantarovich D; Dantal J; Blancho G; Josien R; Ancelet D; Soulillou JP
    J Am Soc Nephrol; 2001 Aug; 12(8):1758-1763. PubMed ID: 11461950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
    Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
    Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
    Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
    Isenberg AL; Shen GK; Singh TP; Hahn A; Conti DJ
    Clin Transplant; 2000 Jun; 14(3):193-8. PubMed ID: 10831076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation.
    Satoh S; Tada H; Murakami M; Tsuchiya N; Inoue T; Togashi H; Matsuura S; Hayase Y; Suzuki T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1751-3. PubMed ID: 15919454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
    Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
    Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.